Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Fareed

Showing results (121-130 of 384) with videos related to

Pageof 39
Sort By:
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 22, 2000
Thrombolytic drugs in acute myocardial infarctionO Iqbal, H Messmore, D Hoppensteadt, et al.
Seminars in Thrombosis and Hemostasis|October 1, 1983
Newer synthetic peptide substrates in coagulation testing: some practical considerations for automated methodsL G Svendsen, J Fareed, J M Walenga, et al.
Thrombosis Research|February 1, 1993
Studies on the pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after intravenous and subcutaneous administration in dogsL Iyer, M Koza, O Iqbal, et al.
Thrombosis Research|November 1, 1996
Defibrotide mediated inhibition of serotonin, endothelin-I, thromboxane, and serum induced contraction of canine femoral and pulmonary arterial ringsL H Yang, D A Hoppensteadt, O Iqbal, et al.
Seminars in Thrombosis and Hemostasis|June 5, 1999
Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implicationsS Haas, J M Walenga, W P Jeske, et al.
Thrombosis Research|March 14, 2000
A synthetic inhibitor of factor Xa, DX-9065a, reduces proliferation of vascular smooth muscle cells in vivo in ratsB Kaiser, M Paintz, O Scholz, et al.
International Angiology : a Journal of the International Union of Angiology|March 1, 1996
Physical and pharmacologic manipulation of the vascular system as measured by the release of TFPI and other mediators of antithrombotic actionsD A Hoppensteadt, W Jeske, J Fareed, et al.
The American Journal of Cardiology|September 16, 1998
Rationale for the management of coronary syndromes with low-molecular-weight heparinsE Gurfinkel, J Fareed, E Antman, et al.
The Medical Clinics of North America|May 1, 1994
Current trends in the development of anticoagulant and antithrombotic drugsJ Fareed, D Hoppensteadt, J M Walenga, et al.
Critical Reviews in Clinical Laboratory Sciences|January 1, 1986
In vitro evaluation of heparin fractions: old vs. new methodsJ M Walenga, J Fareed, D Hoppensteadt, et al.
Pageof 39

Showing results (121-130 of 384) with videos related to

Sort By:
Pageof 39
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 22, 2000
Thrombolytic drugs in acute myocardial infarctionO Iqbal, H Messmore, D Hoppensteadt, et al.
Seminars in Thrombosis and Hemostasis|October 1, 1983
Newer synthetic peptide substrates in coagulation testing: some practical considerations for automated methodsL G Svendsen, J Fareed, J M Walenga, et al.
Thrombosis Research|February 1, 1993
Studies on the pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after intravenous and subcutaneous administration in dogsL Iyer, M Koza, O Iqbal, et al.
Thrombosis Research|November 1, 1996
Defibrotide mediated inhibition of serotonin, endothelin-I, thromboxane, and serum induced contraction of canine femoral and pulmonary arterial ringsL H Yang, D A Hoppensteadt, O Iqbal, et al.
Seminars in Thrombosis and Hemostasis|June 5, 1999
Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implicationsS Haas, J M Walenga, W P Jeske, et al.
Thrombosis Research|March 14, 2000
A synthetic inhibitor of factor Xa, DX-9065a, reduces proliferation of vascular smooth muscle cells in vivo in ratsB Kaiser, M Paintz, O Scholz, et al.
International Angiology : a Journal of the International Union of Angiology|March 1, 1996
Physical and pharmacologic manipulation of the vascular system as measured by the release of TFPI and other mediators of antithrombotic actionsD A Hoppensteadt, W Jeske, J Fareed, et al.
The American Journal of Cardiology|September 16, 1998
Rationale for the management of coronary syndromes with low-molecular-weight heparinsE Gurfinkel, J Fareed, E Antman, et al.
The Medical Clinics of North America|May 1, 1994
Current trends in the development of anticoagulant and antithrombotic drugsJ Fareed, D Hoppensteadt, J M Walenga, et al.
Critical Reviews in Clinical Laboratory Sciences|January 1, 1986
In vitro evaluation of heparin fractions: old vs. new methodsJ M Walenga, J Fareed, D Hoppensteadt, et al.
Pageof 39